CELG RT — Bristol-Myers Squibb Co Balance Sheet
0.000.00%
- $88.81bn
- $124.44bn
- $48.30bn
- 88
- 91
- 70
- 97
Annual balance sheet for Bristol-Myers Squibb Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 15,831 | 17,221 | 9,253 | 12,280 | 10,859 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,501 | 12,516 | 13,937 | 15,264 | 14,424 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 30,192 | 33,262 | 27,273 | 31,770 | 29,780 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,745 | 6,968 | 7,475 | 8,036 | 8,360 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 118,481 | 109,314 | 96,820 | 95,159 | 92,603 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19,080 | 21,868 | 21,890 | 22,262 | 23,774 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 80,659 | 73,368 | 65,759 | 65,729 | 76,268 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 37,822 | 35,946 | 31,061 | 29,430 | 16,335 |
| Total Liabilities & Shareholders' Equity | 118,481 | 109,314 | 96,820 | 95,159 | 92,603 |
| Total Common Shares Outstanding |